| Identification | More | [Name]
Lafutidine | [CAS]
118288-08-7 | [Synonyms]
togar
LACTITOL
frg-8813
LAFUTIDINE
Protecadin
Laflutidine
118288-08-07
enyl)acetamide
Adefovir Dipivioxil
(z)-inyl)oxy)-2-butenyl)
LAFUTIDINE(SUBJECTTOPATENTFREE)
(+-)-2-(furfurylsulfinyl)-n-(4-(4-(piperidinomethyl)-2-pyridyl)oxy-(z)-2-but
n-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide
acetamide,2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyrid
(Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)
2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((4-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide
2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]acetamide
(Z)-2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide | [EINECS(EC#)]
601-513-8 | [Molecular Formula]
C22H29N3O4S | [MDL Number]
MFCD00867520 | [Molecular Weight]
431.55 | [MOL File]
118288-08-7.mol |
| Chemical Properties | Back Directory | [Melting point ]
92.7-94.9° | [Boiling point ]
704.2±60.0 °C(Predicted) | [density ]
1.252±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMF:5.0(Max Conc. mg/mL);11.59(Max Conc. mM)
DMSO:48.67(Max Conc. mg/mL);112.77(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.21(Max Conc. mM)
Ethanol:9.0(Max Conc. mg/mL);20.86(Max Conc. mM) | [Water Solubility ]
Insoluble in water | [form ]
powder to crystal | [pka]
13.13±0.46(Predicted) | [color ]
White to Orange to Green | [Usage]
Second generation histamine H2-receptor antagonist. Antiulcerative | [CAS DataBase Reference]
118288-08-7(CAS DataBase Reference) |
| Questions And Answer | Back Directory | [Description]
Lafutidine is a second generation of H2-receptor antagonist. H2-receptor antagonist can strongly inhibit gastric acid secretion compared with conventional drugs such as antacids. Unlike conventional H2-receptor antagonist, lafutidine inhibits gastric acid secretion during daytime as well as nighttime in clinical studies in humans. Lafutidine also has gastroprotective activity independent of its acid antisecretory efficacy, preventing noxious agent-induced gastric mucosal injury and accelerating the repair process following gastric mucosal damage. It also protects experimentally induced reflux esophagitis, indomethacin-induced intestinal, and dextran sulfate sodium-induced colonic inflammation.
Lafutidine is used for gastric and duodenal ulcers. It is also confirmed that lafutidine can be used as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.
| [References]
[1] Tomohiko Shimatani, Masaki Inoue, Tomoko Kuroiwa, Jing Xu, Masuo Nakamura, Susumu Tazuma, Kazuro Ikawa, Norifumi Morikawa (2006) Lafutidine, a Newly Developed Antiulcer Drug, Elevates Postprandial Intragastric pH and Increases Plasma Calcitonin Gene-Related Peptide and Somatostatin Concentrations in Humans: Comparisons with Famotidine, Digestive Diseases and Sciences, 51, 114-120
[2] Bhupesh Dewan, Nisha Philipose (2011) Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial, Gastroenterology Research and Practice, 2011, Article ID 640685
[3] https://www.drugs.com
|
| Hazard Information | Back Directory | [Originator]
Fujirebio (Japan) | [Uses]
Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion | [Uses]
Second generation histamine H2-receptor antagonist. Antiulcerative | [Definition]
ChEBI: Lafutidine is an organic molecular entity. | [Brand name]
Stogar, Protecadin |
|
|